about
Renal artery sympathetic denervation: observations from the UK experience.Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials.Association of left atrial volume with mortality among ESRD patients with left ventricular hypertrophy referred for kidney transplantation.Hyperresponders vs. nonresponder patients after renal denervation: do they differ?Effect of left atrial and ventricular abnormalities on renal transplant recipient outcome-a single-center study.Microvolt T-wave alternans in end-stage renal disease patients--associations with uremic cardiomyopathy.Fibroblast growth factor 23 predicts left ventricular mass and induces cell adhesion molecule formationSerum phosphate and social deprivation independently predict all-cause mortality in chronic kidney diseaseEffect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysisEndothelial dysfunction in renal transplant recipients.Diagnostic, prognostic, and therapeutic implications of brain natriuretic peptide in dialysis and nondialysis-dependent chronic renal failure.Vascular function assessed with cardiovascular magnetic resonance predicts survival in patients with advanced chronic kidney disease.Renal transplantation is not associated with regression of left ventricular hypertrophy: a magnetic resonance study.The cholesterol paradox is flawed; cholesterol must be lowered in dialysis patients.Defining myocardial tissue abnormalities in end-stage renal failure with cardiac magnetic resonance imaging using native T1 mapping.Determinants of left ventricular mass and hypertrophy in hemodialysis patients assessed by cardiac magnetic resonance imaging.Research cardiac magnetic resonance imaging in end stage renal disease - incidence, significance and implications of unexpected incidental findings.Biomarkers of Tolerance in Kidney Transplantation: Are We Predicting Tolerance or Response to Immunosuppressive Treatment?Effect of A Reduction in glomerular filtration rate after NEphrectomy on arterial STiffness and central hemodynamics: rationale and design of the EARNEST study.Inter-study reproducibility of arterial spin labelling magnetic resonance imaging for measurement of renal perfusion in healthy volunteers at 3 Tesla.Blood pressure changes after renal denervation at 10 European expert centers.Native T1 mapping: inter-study, inter-observer and inter-center reproducibility in hemodialysis patients.How is the heart best protected in chronic dialysis patients?: Is there life in the old drugs yet? Mineralocorticoid receptor antagonism for cardiovascular prevention in chronic dialysis patients.Cardiovascular morbidity and mortality after kidney transplantation.Diagnosis and treatment of early renal disease in patients with type 2 diabetes mellitus: what are the clinical needs?New Model for Estimating Glomerular Filtration Rate in Patients With Cancer.Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and theChanges in Kidney Function in a Population With Essential Hypertension in Real Life Settings.Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and tRisk factors and outcome of stroke in renal transplant recipients.Renal artery and parenchymal changes after renal denervation: assessment by magnetic resonance angiography.Hypertension, antihypertensive agents and outcomes following renal transplantation.Risk Factors of Ischemic Stroke and Subsequent Outcome in Patients Receiving Hemodialysis.Obstetric and long-term kidney outcomes in renal transplant recipients: a 40-yr single-center study.Association between serum phosphate and calcium, long-term blood pressure, and mortality in treated hypertensive adults.Cardiomyopathy induced by performance enhancing drugs in a competitive bodybuilder.Renal association clinical practice guideline in post-operative care in the kidney transplant recipientMyocardial changes in incident haemodialysis patients over 6-months: an observational cardiac magnetic resonance imaging study.Gadolinium contrast may be risky in kidney disease.Is this really a true case of NSF following Gadovist exposure alone?
P50
Q27322771-B8A137EA-E16C-4C26-822B-DA332CA3AA91Q31118791-BE30A264-2719-4399-A06D-ABA95495959AQ33975412-F14C1CB6-131B-4586-B3BD-B68DA4852E9FQ34666125-67670B78-EA8E-4028-B348-9A3573AA757DQ34667281-888ABE48-E5A4-4908-AC1D-25A9F14687DCQ34857667-3F0560F5-BA0F-43F4-A215-A504E4B7A1C5Q35157648-A79E0CAE-E344-4E80-B562-8BAA2A5F5750Q35857872-FD96D9C3-5672-4296-84B0-B5AC426BC3B4Q36127484-B49DE58B-C87D-44E4-8356-B17B92E1FEADQ36357239-4FAF1AB4-F5AD-4C7F-926A-2B027EE83BCEQ36715857-3C12217B-B92F-4892-86A5-7F4B7BA5560AQ36862427-EEA8A3C3-7AF4-4197-9900-E8113E2901B6Q36947293-C289CE95-23E5-46E2-9E9A-28D7892337FEQ36996671-06D20273-55C5-4D9C-A502-A9CD5AE89FCBQ37280134-59146002-2EB0-4CE5-8814-694883208341Q37330316-FBB93C27-A6A0-41BC-8711-8F042FC9B0BEQ37452701-3548C255-E122-40D0-A0E4-FAAA343052C7Q37462039-1D65AFAF-D7E4-4B98-A37F-B71A472F46E6Q37522761-EBA69231-3EE6-419B-8A82-5CC6C17B4BB9Q37540953-BC4FED10-2516-4530-ACC2-87AEB2D41D4DQ37598844-CC564F5C-8638-4450-ACED-E4DF9279D780Q37668262-96F78D34-91EE-422F-90D7-593999BE6CC3Q38185467-C77FAB4A-EC47-47EE-86A6-402D0AEEF6C4Q38235860-738C9540-0CAF-4BF6-A58D-A70A256BA000Q38553908-399C54F6-45A0-4EE8-B8E3-7CF16C5922E4Q38689410-DBD4881F-8A02-4E59-8383-B2DB8F14040DQ38740191-1FAF8CFB-948C-47E2-B3CF-C2302244EA23Q38748042-3933F967-0F6C-45A5-A2FD-441AE8FB6C51Q38762047-8B7464AD-DA2A-4BE2-AB79-3A1B0E1FCD07Q39740806-3B7CA2F5-129B-4845-A0CC-F630FF6CBDC8Q40303410-D429075A-AA2D-44C7-85A8-5F6DC65A9E31Q40441710-EEC6D20D-8729-4B4C-8BA2-91C5A532B38AQ40673213-9DBCA223-2E5B-4646-831B-C70D0019BD62Q40845063-72AC9C46-A592-4334-9FA2-82430646F3D6Q41270928-3B069A29-BC9B-4820-9352-B9B02088B7EBQ41894680-58B61735-176B-4F26-9EB8-D9FA746064E4Q42343473-A0D10FB5-2BD0-438A-B977-7B4F167C5211Q42630377-0880D99F-80CE-4CB5-9C1E-9BE427469982Q42722526-C6426F96-21B0-48F3-A945-4C0C82D599E3Q43179469-31C6411E-8949-4CAF-ABA6-03D488C5DF2F
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Patrick B Mark
@ast
Patrick B Mark
@en
Patrick B Mark
@es
Patrick B Mark
@nl
Patrick B Mark
@sl
type
label
Patrick B Mark
@ast
Patrick B Mark
@en
Patrick B Mark
@es
Patrick B Mark
@nl
Patrick B Mark
@sl
altLabel
Patrick Mark
@en
prefLabel
Patrick B Mark
@ast
Patrick B Mark
@en
Patrick B Mark
@es
Patrick B Mark
@nl
Patrick B Mark
@sl
P1053
N-5536-2014
P106
P21
P31
P3829
P496
0000-0003-3387-2123